Aberdeen Group plc Increases Holdings in Vaxcyte, Inc. $PCVX
Aberdeen Group plc significantly increased its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 35.6% during the fourth quarter, now holding 979,765 shares valued at approximately $45.2 million. Despite this increased institutional interest, Vaxcyte reported a Q4 EPS miss, remains unprofitable, and saw insider selling last quarter. Analysts maintain a "Moderate Buy" rating with a consensus price target of $86.00.
Vaxcyte (PCVX) Valuation Check As VAX-31 Phase 3 OPUS Trials Reach Full Enrollment
Vaxcyte (PCVX) has fully enrolled its OPUS-1 and OPUS-2 Phase 3 trials for VAX-31, a significant step that could lead to a Biologics License Application. Despite a 25.66% share price increase over 90 days, the stock is currently trading at US$58.38, which is considered undervalued against a narrative fair value of $109. The valuation hinges on the success of VAX-31 trials and Vaxcyte's ability to manage R&D and manufacturing costs.
PCVX.O Technical Analysis & Stock Price Forecast
The technical analysis for Vaxcyte Inc (PCVX) as of April 2, 2026, indicates a "Strong Buy" consensus from Intellectia's proprietary analysis, with 9 buy signals and 4 sell signals among 13 technical indicators. Key metrics like MACD and various moving averages suggest a bullish outlook, while the RSI sits in neutral territory at 56.746. The stock is trading above its 60-day and 200-day moving averages, with immediate resistance identified at $59.484 and strong support at $52.534.
Insider Sell Alert: Jim Wassil Sells 2,250 Shares of Vaxcyte Inc (PCVX)
Jim Wassil, the Chief Operating Officer of Vaxcyte Inc, sold 2,250 shares of the company on April 1, 2026, reducing his holdings to 162,994 shares. This transaction follows a pattern of insider selling at Vaxcyte, with no insider buys in the past year against six insider sells. The shares were trading at $58.43, giving the company a market capitalization of $8.402 billion at the time of the sale.
Vaxcyte (PCVX) COO sells 2,250 shares in planned Rule 10b5-1 trades
Vaxcyte, Inc.'s Chief Operating Officer, Jim Wassil, sold 2,250 shares of common stock on April 1, 2026, through a pre-arranged Rule 10b5-1 trading plan. The shares were sold in two separate transactions at weighted-average prices of $58.138 and $58.932. Following these sales, Wassil directly owns 162,994 shares, and the filing also notes prior share transfers to his ex-spouse as part of a divorce settlement.
PCVX SEC Filings - Vaxcyte, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Vaxcyte, Inc. (PCVX) SEC filings, including 10-K, 10-Q, and 8-K reports, as well as insider trading notifications. It details the company's financial communications, material agreements, and key milestones in its vaccine development, offering AI-generated summaries and sentiment analysis for each filing. Recent filings cover significant ownership stakes, stock offerings, and insider share transfers, alongside financial results and commercial manufacturing agreements.
PCVX SEC Filings - Vaxcyte, Inc. 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides a comprehensive resource for Vaxcyte, Inc. (PCVX) SEC filings, including annual 10-K, quarterly 10-Q, material event 8-K, and insider trading Form 4 reports. It describes Vaxcyte as a clinical-stage vaccine innovation company with a focus on its pneumococcal conjugate vaccine franchise. The platform offers near real-time updates on filings, AI-generated summaries, and analysis of key financial and operational details.
PCVX Should I Buy
This article provides an analysis of Vaxcyte Inc (PCVX), recommending it as a "Buy" for long-term investors. It highlights strong technical indicators, favorable analyst ratings with significant upside potential, and positive catalysts like promising clinical developments for its key product, VAX-31. Despite current financial losses as the company is in a growth phase, the analysis suggests it's a compelling long-term investment.
James Wassil sells 7,395 PCVX shares (NASDAQ: PCVX)
James Wassil sold 7,395 shares of Vaxcyte, Inc. (NASDAQ: PCVX) common stock on March 10, 2026, for a total of $435,438.31, according to a Form 144 SEC filing by UBS Financial Services, Inc. The filing also disclosed RSU vesting amounts of 783 shares on February 28, 2025, and 1,467 shares on March 2, 2025. This transaction was deemed to have a neutral filing impact and sentiment.
Vaxcyte, Inc. (NASDAQ:PCVX) Given Average Rating of "Moderate Buy" by Brokerages
Vaxcyte, Inc. (NASDAQ:PCVX) has received a "Moderate Buy" consensus rating from nine brokerages, with an average 12-month price target of $86.00. Despite recent insider selling totaling approximately $687,031, institutional investors have increased their stakes, with 96.78% of the stock owned by institutions. The clinical-stage biotechnology company, focused on developing preventive vaccines, recently missed its EPS estimates for the last quarter.
(PCVX) and the Role of Price-Sensitive Allocations
This article analyzes Vaxcyte Inc. (NASDAQ: PCVX), highlighting a positive near-term sentiment with a potential to overcome a mid-term weak bias within a long-term strength context. It details a mid-channel oscillation pattern and an exceptional 41.0:1 risk-reward setup, targeting a 11.9% gain with only 0.3% risk. The report also outlines three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with a multi-timeframe signal analysis.
Vaxcyte joins elite club of stocks with RS ratings over 90
Vaxcyte (PCVX) has achieved an RS Rating of 91, placing it among the top growth stocks. The company's unique pneumococcal vaccine candidate (Vax-24) targets a broad range of serotypes, with promising trial results for elderly and pediatric populations. The strong Relative Strength rating indicates that Vaxcyte has outperformed 91% of all stocks in terms of price performance over the past year.
Certain Common Stock of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2026.
Vaxcyte, Inc. common stock is subject to a 61-day lock-up agreement from January 29, 2026, to March 31, 2026. This agreement restricts executive officers and directors from selling or transferring their shares or related securities without the consent of BofA Securities, Inc., following a recent offering. The measure is intended to stabilize the stock price after the offering.
Vanguard disaggregates holdings; PCVX ownership shown as 0 (PCVX)
Vanguard's recent Schedule 13G/A filing for Vaxcyte Inc (PCVX) reports zero beneficial ownership and 0% of common stock. This change is due to an internal realignment on January 12, 2026, where Vanguard subsidiaries will now report their holdings separately, in reliance on SEC Release No. 34-39538. The filing clarifies that this is a reporting structure amendment, not an economic divestment, and investors should consult subsequent filings from Vanguard's subsidiaries for specific ownership details.
Assenagon Asset Management S.A. Increases Position in Vaxcyte, Inc. $PCVX
Assenagon Asset Management S.A. significantly increased its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 147.7% in the fourth quarter, now holding 544,728 shares valued at approximately $25.13 million. This comes as institutional investors own 96.78% of the company, despite some recent insider share sales. Vaxcyte reported a Q4 EPS miss, but analysts maintain a "Moderate Buy" consensus with an average target price of $94.50.
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Vaxcyte has completed enrollment for its OPUS-1 and OPUS-2 Phase 3 trials, which are evaluating VAX-31, a 31-valent pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease and pneumonia in adults. The OPUS-1 trial, with approximately 4,000 participants, compares VAX-31 against existing vaccines, with topline data expected in Q4 2026. The OPUS-2 trial, involving about 1,300 participants, assesses VAX-31's effectiveness when co-administered with a seasonal influenza vaccine, with results anticipated in H1 2027.
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Vaxcyte has announced the completion of enrollment for its OPUS-1 and OPUS-2 Phase 3 clinical trials, investigating VAX-31, a 31-valent pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease and pneumonia in adults. The OPUS-1 trial, with approximately 4,000 participants, is designed to compare VAX-31 against current standard-of-care vaccines, with topline data expected in Q4 2026. The OPUS-2 trial, involving 1,300 participants, evaluates VAX-31's effectiveness when co-administered with a seasonal influenza vaccine, with results anticipated in H1 2027.
Vaxcyte (PCVX) Completes Enrollment for Key Phase 3 Trials
Vaxcyte (PCVX) has completed enrollment for its VAX-31 OPUS-1 and OPUS-2 Phase 3 trials, marking a significant step in its vaccine development. The biotechnology company, with a market capitalization of $7.87 billion, is focused on engineering high-fidelity vaccines, but currently reports no revenue and faces challenges in profitability, despite strong liquidity and minimal debt. Investors are advised to consider these financial aspects alongside the promising pipeline and inherent risks of clinical-stage biotech firms.
Vaxcyte fills key adult vaccine trial, sets up 2026 Phase 3 data
Vaxcyte (PCVX) has announced the completion of enrollment for its OPUS-1 and OPUS-2 Phase 3 trials, evaluating its 31-valent pneumococcal conjugate vaccine candidate, VAX-31, for preventing invasive pneumococcal disease and pneumonia in adults. Topline data for OPUS-1 is expected in Q4 2026, with further results from OPUS-2 and OPUS-3 (which is still enrolling) anticipated in H1 2027. This progress aligns with FDA requirements for a planned Biologics License Application (BLA) submission, aiming to set a new standard of care with broader serotype coverage and high immunogenicity.
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Vaxcyte, Inc. has announced the completion of enrollment for its OPUS-1 and OPUS-2 Phase 3 trials, evaluating VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate. These trials aim to assess the vaccine's safety, tolerability, and immunogenicity for preventing invasive pneumococcal disease (IPD) and pneumonia in adults, with topline data from OPUS-1 expected in Q4 2026 and OPUS-2/OPUS-3 results in H1 2027. VAX-31 holds Breakthrough Therapy designation from the FDA for both IPD and pneumonia prevention in adults, and Vaxcyte believes it has the potential to set a new standard of care due to its broad serotype coverage.
Will VAX-31’s Phase 3 OPUS Progress and Broader Serotype Coverage Change Vaxcyte’s (PCVX) Narrative
Vaxcyte's VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, has progressed to the OPUS Phase 3 adult program after showing strong immune responses and a safety profile comparable to Prevnar 20 in a Phase 1/2 study. This advancement, coupled with its broader serotype coverage, strengthens Vaxcyte's investment narrative, although the company faces significant cash burn and high R&D costs. The success of ongoing clinical trials is crucial to support substantial investments and realize projected revenue and earnings growth by 2029.
Assessing Vaxcyte (PCVX) Valuation After Strong VAX 31 Phase 1/2 Results In The Lancet
Vaxcyte (PCVX) has released strong VAX-31 Phase 1/2 results in The Lancet Infectious Diseases, showing favorable safety and immune responses, supporting progression to Phase 3 trials. Despite a recent share price decline over one year, the stock's five-year return is positive, and it is currently regarded as undervalued by analysts, with a fair value estimate of $109 against its current trading price of $54.65. The company's valuation also relies on the successful completion of a large-scale manufacturing facility and continued R&D investment.
Vaxcyte Announces Significant Development of First-of-Its-Kind PCV31
Vaxcyte has announced significant progress in the clinical development of VAX-31, its 31-valent pneumococcal conjugate vaccine (PCV31) candidate. This vaccine, the highest-valent PCV currently in development, aims to provide comprehensive protection against pneumococcal disease for adults and infants, targeting a broad spectrum of IPD-causing serotypes. The ongoing OPUS-2 and upcoming OPUS-3 trials will evaluate its performance in various adult populations, including co-administration with flu vaccines and in those previously immunized with other PCVs, with topline data expected in late 2026 and early 2027.
PCVX PE Ratio & Valuation, Is PCVX Overvalued
Vaxcyte Inc (PCVX) is currently in the "Fair zone" with a forward P/S ratio of 162.18, which is significantly higher than its five-year average. The article indicates that PCVX's P/S ratio is 339.48% above the industry average, suggesting this premium might be unsustainable despite robust revenue growth. Key valuation metrics like P/B ratio and FCF yield are also analyzed, comparing current figures to historical averages and industry benchmarks.
Vaxcyte (PCVX) finance SVP sells 1,892 shares under 10b5-1 plan
Vaxcyte's SVP of Finance & CAO, Elvia Cowan, sold 1,892 shares of common stock on March 17, 2026, under a pre-arranged Rule 10b5-1 trading plan. The sales occurred at weighted-average prices of $55.387 and $56.263 per share. Following these transactions, Cowan directly holds 28,975 shares of Vaxcyte common stock.
PCVX - Future Late Stage Vaccine Programs And Manufacturing Capacity Will Drive Long Term Opportunity
Vaxcyte (PCVX) is positioned for long-term growth due to its late-stage pneumococcal and Group A Strep vaccine trials and significant investment in manufacturing capacity. Analysts forecast substantial revenue growth by 2029, though profitability is not expected in the next three years. Key risks include high R&D costs, potential regulatory setbacks, and competition from major pharmaceutical companies.
Insider Sell: Elvia Cowan Sells 1,892 Shares of Vaxcyte Inc (PCVX)
Elvia Cowan, Senior Vice President, Finance & Chief Accounting Officer at Vaxcyte Inc (PCVX), sold 1,892 shares of the company on March 17, 2026. This transaction increased her total sales over the past year to 16,015 shares, with no purchases. Vaxcyte Inc, a biotechnology company, was trading at $55.57 per share at the time of the sale, resulting in a market capitalization of $7.813 billion.
Vaxcyte (NASDAQ:PCVX) CAO Sells $105,138.44 in Stock
Vaxcyte's CAO, Elvia Cowan, recently sold 1,892 shares of the company's stock for $105,138.44, reducing her stake by 6.13%. The sale occurred amidst the stock trading down 2.2% and an earnings miss of ($1.80) EPS for the quarter. Despite the insider selling and missed earnings, analysts maintain a "Moderate Buy" rating with an average target price of $94.50.
Vaxcyte (PCVX) Price Target Decreased by 17.52% to 83.49
The price target for Vaxcyte (PCVX) has been decreased by 17.52%, bringing it down to $83.49. This adjustment reflects a significant change in the outlook for the company's stock.
Vaxcyte SVP, finance & CAO Cowan sells $105k in stock
Elvia Cowan, SVP, Finance & CAO at Vaxcyte, Inc. (NASDAQ:PCVX), sold 1,892 shares of common stock for approximately $105,146 on March 17, 2026, through a pre-arranged trading plan. This transaction follows other significant financial activities by Vaxcyte, including recent public offerings raising substantial capital. Analysts have maintained "Buy" ratings and increased price targets for Vaxcyte, citing its strong pipeline and financial position.
A 31-strain pneumonia shot showed strong immune responses in adults 50+
Vaxcyte (Nasdaq: PCVX) announced the publication of positive Phase 1/2 adult data for VAX-31 in The Lancet Infectious Diseases, showing strong immune responses across all 31 serotypes and a safety profile similar to Prevnar 20. The VAX-31 High Dose met or exceeded non-inferiority criteria for 20 shared serotypes and superiority for 11 incremental serotypes compared to PCV20. Vaxcyte is now evaluating VAX-31 in a comprehensive OPUS Phase 3 adult program, with topline data expected in Q4 2026, aiming to offer the broadest-spectrum pneumococcal conjugate vaccine available.
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
Vaxcyte, Inc. announced the publication of positive VAX-31 adult Phase 1/2 clinical study results in The Lancet Infectious Diseases. The study showed that VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate, was well-tolerated and demonstrated robust immune responses across all 31 serotypes in adults aged 50 and older, with a safety profile similar to Prevnar 20®. Based on these results, VAX-31 High Dose has advanced into a comprehensive Phase 3 adult program, aiming to provide broader protection against invasive pneumococcal disease and pneumonia.
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases
Vaxcyte, Inc. announced the publication of positive results from its VAX-31 adult Phase 1/2 clinical study in The Lancet Infectious Diseases. The study demonstrated that VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, was well-tolerated and elicited robust immune responses across all 31 serotypes in adults aged 50 and older. These findings support the progression of VAX-31 into a comprehensive Phase 3 adult program, aiming to provide broader protection against pneumococcal disease than current standard-of-care vaccines.
Elvia Cowan sells shares; RSU vesting at PCVX (NASDAQ: PCVX)
A recently filed Form 144 indicates that Elvia Cowan, an insider at PCVX (Vaxcyte, Inc.), sold shares totaling $556,971.85 on December 23, 2025, and an additional $146,481.75 on March 11, 2026. The filing also reports several RSU vesting events for Cowan, totaling 1,892 shares, on various dates in late February and early March 2026. These transactions are routine disclosures required for the sale of restricted or control securities.
Vaxcyte, Inc. $PCVX Shares Sold by Aquatic Capital Management LLC
Aquatic Capital Management LLC reduced its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 39.0% in the third quarter, now owning 125,785 shares valued at $4,531,000. Other institutional investors also adjusted their holdings, while insiders like COO Jim Wassil and SVP Elvia Cowan sold significant shares. Despite some insider selling and a missed earnings estimate, analysts maintain a "Moderate Buy" consensus rating for Vaxcyte with an average target price of $94.50.
HighVista Strategies LLC Acquires 53,345 Shares of Vaxcyte, Inc. $PCVX
HighVista Strategies LLC significantly increased its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 159.4% in the third quarter, acquiring an additional 53,345 shares to own a total of 86,802 shares valued at approximately $3.13 million. Despite recent insider selling, institutional investors collectively own 96.78% of the stock. Analysts currently rate Vaxcyte as a "Moderate Buy" with an average price target of $94.50, suggesting substantial upside potential from its current trading price of around $54.58.
PCVX Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Vaxcyte Inc (PCVX), indicating a "Neutral" overall technical sentiment. It details various technical indicators like RSI, MACD, moving averages, and support/resistance levels, with the stock currently trading above its 60-day and 200-day moving averages.
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
Vaxcyte, Inc. announced it will report its financial results for the fourth quarter and full year 2025 and provide a business update on February 24, 2026, after market close. The company will host a conference call and webcast to discuss these results and updates. Vaxcyte is a clinical-stage vaccine innovation company focused on developing high-fidelity vaccines, including several pneumococcal conjugate vaccine (PCV) candidates and other prophylactic vaccines.
Vaxcyte, Inc. $PCVX Shares Acquired by Boothbay Fund Management LLC
Boothbay Fund Management LLC increased its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 24.7% during the third quarter, now owning 128,731 shares valued at $4.64 million. Several other institutional investors also modified their holdings, with Vanguard Group Inc. being the largest holder. Despite recent insider selling, analysts hold a "Moderate Buy" rating for Vaxcyte with an average price target of $94.50.
Pivotal bioVenture Partners Investment Advisor LLC Raises Stock Position in Vaxcyte, Inc. $PCVX
Pivotal bioVenture Partners Investment Advisor LLC increased its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 5.2% in the third quarter, making Vaxcyte its largest holding at 28.6% of its portfolio and valued at $49.4 million. Other institutions also increased their positions, resulting in institutional investors owning approximately 96.78% of the company's stock. Despite mixed analyst ratings and a recent earnings miss, Vaxcyte maintains an average "Moderate Buy" rating and a target price of $94.50.
Pivotal bioVenture Partners Boosts Stake in Vaxcyte
Pivotal bioVenture Partners Investment Advisor LLC increased its stake in Vaxcyte, Inc. by 5.2% in Q3 2026, making it the biotech company's largest institutional shareholder with a 1.05% ownership stake valued at $49.4 million. This increased investment suggests the firm's confidence in Vaxcyte's pipeline of preventive vaccines for serious bacterial diseases and its future growth prospects. Vaxcyte now represents 28.6% of Pivotal bioVenture Partners' total portfolio, indicating a significant commitment to the company.
Vaxcyte, Inc. $PCVX Holdings Lowered by Capital Research Global Investors
Capital Research Global Investors significantly reduced its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 82.3% in the third quarter, selling over 3.9 million shares. Despite this, institutional ownership remains high at 96.78%, while insiders have been net sellers. The company recently missed its EPS consensus, but analysts maintain a "Moderate Buy" rating with an average price target of $94.50.
Vaxcyte Inc Stock (ISIN: US92242T1016) Slides on Major Investor Stake Cut
Vaxcyte Inc stock experienced a decline after Capital Research Global Investors significantly reduced its stake in the company by 82.3%, selling nearly 4 million shares. This move has raised questions about investor sentiment in the clinical-stage vaccine developer and occurred amidst broader volatility in the biotech sector. The article details Vaxcyte's innovative vaccine platform, its competitive landscape, financial health, and risks for investors.
Vaxcyte Shares Decline as Capital Research Global Investors Reduces Stake
Capital Research Global Investors has significantly reduced its stake in Vaxcyte, Inc. by 82.3% in the third quarter, selling nearly 4 million shares. This move leaves the institutional investor with 842,978 shares, valued at approximately $30.4 million, and could signal a shift in sentiment regarding the biotech company's prospects and its vaccine development pipeline. Vaxcyte is a clinical-stage biotech focused on preventive vaccines, including its lead candidate VAX-24.
Vaxcyte (PCVX) finance SVP exercises options and sells 2,500 shares
Vaxcyte's SVP of Finance & CAO, Elvia Cowan, exercised stock options for 2,500 shares at $25.92 per share and subsequently sold these shares at an average price of $58.5927 per share. The transaction, which also involved surrendering 495 shares for tax withholding on RSU vesting, was conducted under a pre-planned Rule 10b5-1 trading plan adopted in December 2025. After these routine transactions, Cowan directly holds 30,867 shares of Vaxcyte common stock.
Vaxcyte (PCVX) COO logs planned stock sales and RSU tax withholding
Vaxcyte, Inc.'s Chief Operating Officer, Jim Wassil, reported recent stock transactions, including the surrender of 975 shares for tax withholding on RSU vesting and the sale of 7,395 common shares under a pre-arranged Rule 10b5-1 trading plan. These sales occurred on March 9 and 10, 2026, at weighted-average prices of $58.316 and $59.160. Following these transactions, Wassil directly holds 166,818 shares, maintaining a substantial equity position in the company.
Vaxcyte (NASDAQ:PCVX) COO Sells $435,417.60 in Stock
Vaxcyte (NASDAQ:PCVX) COO Jim Wassil sold 7,395 shares of company stock for a total of $435,417.60, reducing his stake by 4.24%. The sale, disclosed in an SEC filing, leaves Wassil with 166,818 shares valued at approximately $9.82 million. Despite missing quarterly EPS estimates, analysts generally maintain a "Moderate Buy" rating with an average price target of $94.50.
Vaxcyte (NASDAQ:PCVX) CAO Elvia Cowan Sells 2,500 Shares
Vaxcyte (NASDAQ: PCVX) CAO Elvia Cowan sold 2,500 shares of company stock on March 11th, reducing her holdings by 7.49% to 30,867 shares. This comes after the company reported an EPS loss of ($1.80), missing analyst estimates. Despite the insider selling and missed earnings, analysts generally maintain a "Moderate Buy" rating with a consensus price target of $94.50.
PCVX (NASDAQ: PCVX) affiliate plans sale of 2,500 shares via option exercise
Vaxcyte, Inc. (NASDAQ: PCVX) has filed a Form 144 indicating a proposed sale of 2,500 common shares through the exercise of stock options on March 11, 2026. The filing also notes a previous sale of 11,623 shares on December 23, 2025, for $556,971.85 by Elvia Cowan. While the proposed sale is minor compared to the total outstanding shares of 143,920,361, it provides transparency on insider transactions.
Jefferies Maintains Buy on Vaxcyte (PCVX) March 10, 2026
Jefferies has reiterated its Buy rating on Vaxcyte (PCVX) as of March 10, 2026, driven by the strong potential of the company's adult pneumococcal conjugate vaccine program to significantly enhance its long-term valuation. Despite the reaffirmed bullish stance, no new price target was issued, and the stock saw a modest 0.22% increase following the announcement. Meyka AI also rates PCVX with a 'B' grade, incorporating various financial and market performance metrics.
